Advertisement
Policy Forum

Policy Forum Policy Forum articles provide a platform for health policy makers from around the world to discuss the challenges and opportunities in improving health care to their constituencies.

See all article types »

A Prescription for Improving Drug Formulary Decision Making

  • Gordon D. Schiff mail,

    gschiff@partners.org

    Affiliations: Brigham and Woman's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America

    X
  • William L. Galanter,

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, United States of America, Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, United States of America

    X
  • Jay Duhig,

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, Illinois, United States of America

    X
  • Michael J. Koronkowski,

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, Illinois, United States of America

    X
  • Amy E. Lodolce,

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, Illinois, United States of America

    X
  • Pam Pontikes,

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States of America

    X
  • John Busker,

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States of America

    X
  • Daniel Touchette,

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, Illinois, United States of America

    X
  • Surrey Walton,

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, Illinois, United States of America

    X
  • Bruce L. Lambert

    Affiliations: Center for Education and Research on Therapeutics, University of Illinois at Chicago, Chicago, Illinois, United States of America, Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, United States of America, University of Illinois at Chicago, Department of Pharmacy Administration, Chicago, Illinois, United States of America

    X
  • Published: May 22, 2012
  • DOI: 10.1371/journal.pmed.1001220

Reader Comments (1)

Post a new comment on this article

Mfg Rebates can still tilt the discussion

Posted by JerryS on 25 May 2012 at 20:08 GMT

I spent my last 8 professional years working with health care companies as they developed and then implemented their formularies and in each and every case, the size of the discount or manufacturers rebate stood head and shoulders above all other considerations. I saw better drugs discarded or admitted but with a far higher patient copayment requirement. I even see it with the health plan that I have now that I am retired. Yes, it is supposed to be a way to keep cost down but what it really does is increase profits for the healthcare company.

No competing interests declared.